NOVARTIS N 2. LINIENOVARTIS N 2. LINIENOVARTIS N 2. LINIE

NOVARTIS N 2. LINIE

No trades
See on Supercharts

Key facts today

A U.S. District Judge has blocked West Virginia's law requiring Novartis to provide discounts via third-party pharmacies, citing conflicts with federal rules related to the 340B drug discount program.
Analyze the impactAnalyze the impact
Market capitalization
‪172.40 B‬CHF
7.64CHF
‪13.34 B‬CHF
‪40.83 B‬CHF
‪1.75 B‬
Beta (1Y)
0.88
Employees (FY)
‪76.06 K‬
Change (1Y)
‪−25.65 K‬ −25.22%
Revenue / Employee (1Y)
‪536.90 K‬CHF
Net income / Employee (1Y)
‪101.24 K‬CHF

About NOVARTIS N


CEO
Vasant Narasimhan
Headquarters
Basel
Founded
1996
ISIN
CH0038459415
FIGI
BBG0027FDTP9
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.68%
Maturity date
Aug 14, 2050
N
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
5.90%
Maturity date
Nov 20, 2045
N
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.72%
Maturity date
May 6, 2044
N
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.72%
Maturity date
Sep 18, 2054
N
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.65%
Maturity date
Sep 21, 2042
N
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
5.25%
Maturity date
Sep 18, 2034
N
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
5.13%
Maturity date
Aug 14, 2030
N
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.88%
Maturity date
Sep 18, 2031
N
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.78%
Maturity date
Sep 18, 2029
N
XPNC
NOVARTIS CAPITAL 15/25
Yield to maturity
4.64%
Maturity date
Nov 20, 2025
N
US66989HAN8
NOVARTIS CAPITAL 17/27
Yield to maturity
4.61%
Maturity date
May 17, 2027

Explore more bonds 

Frequently Asked Questions


The current price of NOVNEE is 86.92 CHF — it has decreased by −0.23% in the past 24 hours. Watch NOVARTIS N 2. LINIE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange NOVARTIS N 2. LINIE stocks are traded under the ticker NOVNEE.
NOVNEE stock has fallen by −1.22% compared to the previous week, the month change is a −4.97% fall, over the last year NOVARTIS N 2. LINIE has showed a 2.88% increase.
NOVNEE reached its all-time high on Jul 20, 2015 with the price of 103.03 CHF, and its all-time low was 47.88 CHF and was reached on Mar 19, 2008. View more price dynamics on NOVNEE chart.
See other stocks reaching their highest and lowest prices.
NOVNEE stock is 1.43% volatile and has beta coefficient of 0.88. Track NOVARTIS N 2. LINIE stock price on the chart and check out the list of the most volatile stocks — is NOVARTIS N 2. LINIE there?
Today NOVARTIS N 2. LINIE has the market capitalization of ‪169.67 B‬, it has increased by 0.89% over the last week.
Yes, you can track NOVARTIS N 2. LINIE financials in yearly and quarterly reports right on TradingView.
NOVNEE net income for the last quarter is ‪2.76 B‬ CHF, while the quarter before that showed ‪2.94 B‬ CHF of net income which accounts for −5.89% change. Track more NOVARTIS N 2. LINIE financial stats to get the full picture.
No, NOVNEE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has ‪76.06 K‬ employees. See our rating of the largest employees — is NOVARTIS N 2. LINIE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVARTIS N 2. LINIE EBITDA is ‪18.02 B‬ CHF, and current EBITDA margin is 44.33%. See more stats in NOVARTIS N 2. LINIE financial statements.
Like other stocks, NOVNEE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVARTIS N 2. LINIE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVARTIS N 2. LINIE technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVARTIS N 2. LINIE stock shows the sell signal. See more of NOVARTIS N 2. LINIE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.